Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
KMDA.OQ - Kamada Ltd
Q3 2024 Kamada Ltd Earnings Call
Nov 13, 2024 / 01:30PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Full capacity, turning now to inhale a therapy, a long term growth catalyst for commodo enrollment continues in the ongoing pivotal phase three innovate clinical trial. As a reminder, earlier this year, we filed an I&D amendment with the US FDA that consisted of a revised statistical analysis trend and study protocol which if approved may allow for the acceleration of the program. We continue to anticipate further D A feedback before the end of this year, as we have said previously, in parallel to the clinical and regulatory progress achieved here, we also continue to have discussions related to the potential partnering of this promising investigational late stage product candidate.
With that. I'll turn the call over to Jai for a detailed
Trustpilot
